Paulmann Maren, Reinkemeier Felix, Lehnhardt Marcus, Mockenhaupt Maja
Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany.
Department of Plastic Surgery and Hand Surgery, Burn Center, Sarcoma Center, Berufsgenossenschaft University Hospital Bergmannsheil Bochum, Bochum, Germany.
Front Med (Lausanne). 2023 Aug 14;10:1125754. doi: 10.3389/fmed.2023.1125754. eCollection 2023.
Generalized bullous fixed drug eruption (GBFDE) is the most severe form of fixed drug eruption and can be misdiagnosed as epidermal necrolysis (EN). We report the case of a 42-year-old male patient presenting with more than 50% skin detachment without defined areas of exanthema or erythema and a history of one prior event of EN caused by acetaminophen (paracetamol), allopurinol, or amoxicillin 1.5 years ago. The initial diagnosis was GBFDE or EN. The histology of a skin biopsy was unable to distinguish between the two diseases. The course of the disease, the later clinical presentation, and the medical and medication history, however, were in favor of a diagnosis of GBFDE with two potentially culprit drugs: metamizole and ibuprofen. Moxifloxacin, enoxaparin sodium, hydromorphone, and insulin human were administered concomitantly, which makes them suspicious as well. Unfortunately, the patient received an additional dose of metamizole, one of the possible causative drugs, and he developed another bullous reaction within 1 month. This led to the diagnosis of GBFDE due to metamizole. This report highlights the challenges of distinguishing two rare diseases and elucidates the importance of distinct clinical presentation and detailed medication history.
泛发性大疱性固定性药疹(GBFDE)是固定性药疹最严重的形式,可被误诊为中毒性表皮坏死松解症(EN)。我们报告了一例42岁男性患者,其皮肤剥脱面积超过50%,无明确的皮疹或红斑区域,且有1.5年前因对乙酰氨基酚(扑热息痛)、别嘌醇或阿莫西林导致的一次EN病史。初步诊断为GBFDE或EN。皮肤活检的组织学检查无法区分这两种疾病。然而,疾病的病程、后来的临床表现以及病史和用药史均支持诊断为GBFDE,有两种潜在的致病药物:安乃近和布洛芬。同时使用了莫西沙星、依诺肝素钠、氢吗啡酮和人胰岛素,这也使它们成为可疑药物。不幸的是,患者又服用了一剂可能的致病药物之一安乃近,1个月内又出现了一次大疱反应。这导致诊断为安乃近所致的GBFDE。本报告强调了区分这两种罕见疾病的挑战,并阐明了独特临床表现和详细用药史的重要性。